Sticking with hormone and CDK4/6 therapy after breast cancer surgery
Part of Cancer, Skin clinical trials.
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have early-stage breast cancer (cancer that has not spread beyond the breast or nearby lymph nodes) that is hormone receptor-positive and HER2-negative.
- You have had surgery to remove your breast tumor.
- You are starting (or have started) hormone therapy combined with a CDK4/6 inhibitor pill, and your doctor approved this treatment plan.
- You are covered by the national health insurance system.
- You are able to understand and agree to participate in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This trial compares two types of CDK4/6 inhibitor pills (dalpiciclib vs. abemaciclib or ribociclib) taken after surgery for early-stage, hormone-positive, HER2-negative breast cancer. The goal is to see which is better tolerated and may help lower the risk of the cancer coming back.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This trial looks at what happens when women with advanced hormone-positive, HER2-negative breast cancer stop taking a CDK4/6 inhibitor after at least a year of successful treatment. The goal is to see if it's safe to take a break from the CDK4/6 inhibitor while continuing hormone therapy alone.
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.